2020
DOI: 10.1007/s11910-020-1025-9
|View full text |Cite
|
Sign up to set email alerts
|

In Vivo Imaging of Neuroinflammatory Targets in Treatment-Resistant Epilepsy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

1
24
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
5
2

Relationship

3
4

Authors

Journals

citations
Cited by 17 publications
(25 citation statements)
references
References 135 publications
1
24
0
Order By: Relevance
“…For example, as demonstrated by findings from studies of animal models of epilepsy and resected human epileptic tissue, sustained neuroinflammation causes chronic hyperexcitability, lower seizure threshold, and neuronal death (Aronica et al, 2010;Maroso et al, 2010;Ravizza et al, 2011;Vezzani and Friedman, 2011;Vezzani et al, 2019). A neuroimaging-based biomarker of neuroinflammation may allow tracking disease progression, treatment response, and associated comorbidities and cognitive impairments; such a tool may even identify a way to prevent these phenomena in the first place (Sharma and Szaflarski, 2020).…”
Section: Introductionmentioning
confidence: 99%
See 3 more Smart Citations
“…For example, as demonstrated by findings from studies of animal models of epilepsy and resected human epileptic tissue, sustained neuroinflammation causes chronic hyperexcitability, lower seizure threshold, and neuronal death (Aronica et al, 2010;Maroso et al, 2010;Ravizza et al, 2011;Vezzani and Friedman, 2011;Vezzani et al, 2019). A neuroimaging-based biomarker of neuroinflammation may allow tracking disease progression, treatment response, and associated comorbidities and cognitive impairments; such a tool may even identify a way to prevent these phenomena in the first place (Sharma and Szaflarski, 2020).…”
Section: Introductionmentioning
confidence: 99%
“…Surgical planning is straightforward in patients with sMRI-detectable lesions, but challenging in the 20-30% patients who are MR-negative (Salmenpera et al, 2007;Jobst and Cascino, 2015;Muhlhofer et al, 2017). Moreover, patients with sMRI-detectable lesions experience 2.5-2.9 times better surgical outcomes than those with normal sMRIs (Salmenpera et al, 2007;Giorgio and De Stefano, 2010;Téllez-Zenteno et al, 2010;Finke, 2018;Alberts et al, 2020;Sharma and Szaflarski, 2020). Despite sMRI's capacity to pinpoint major structural abnormalities (e.g., large ischemic lesions), the data demonstrate its diminished sensitivity and specificity for detecting the smaller, more focalized neuroinflammatory phenomena (Barr Abbreviations: MRSI, Magnetic resonance spectroscopic imaging; MRSI-t, MRSIbased brain temperature; ROI(s), Region(s) of interest; COVrep, Coefficient of variation for repeated measures; SEM, Standard error of measurement; MDC, Minimal Detectable Change; T CRE , MRSI-based brain temperature calculated according to the equation T CRE = −102.…”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations
“…None of these tools alone has the needed sensitivity and specificity for localizing SOZ. Building a hypothesis about the SOZ based on the concordance between these tests' results is key to achieving a favorable surgical outcome [ 10 ]. DRE patients with detectable MRI lesions are 2.5-2.9 times more likely to experience a favorable surgical outcome [ 11 ].…”
Section: Introductionmentioning
confidence: 99%